apl-101
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 5, 2018 (NCT03655613)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05367388 | Phase 1 | May 20, 2022 | Apollomics, Inc. |
| NCT04743505 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Apollomics, Inc., Washington University in St. Louis |
| NCT03655613 | Phase 1/Phase 2 (Phase 2) | Sep 5, 2018 | Apollomics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apollomics, Inc. | For profit | 3 | 2 | 2 | 2018 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1